The principal investigator of HiLo, an NIH Collaboratory Trial, will report on the study’s progress in the next session of PCT Grand Rounds on October 9. HiLo is a pragmatic clinical trial of higher vs lower serum phosphate targets in patients undergoing hemodialysis. The project entered the implementation phase last fall.

Dr. Myles Wolfe of Duke University will present “Pragmatic Trial of Higher vs. Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis (HiLo).” The Grand Rounds session will be held on Friday, October 9, at 1:00 pm eastern. Join the online meeting.

HiLo is supported within the NIH Collaboratory by a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases.